-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
SARS-CoV-2-nsp13-IN-6
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/951588-85-5.gif)
| Category | SARS-CoV |
| CAS | 951588-85-5 |
| Description | SARS-CoV-2 nsp13-IN-6 (compound C5) is a potent SARS-CoV-2 non-structural protein 13 (nsp13) inhibitor with IC50 values of 27 and 33 μM for ssDNA+ ATPase and ssDNA- ATPase. SARS-CoV-2 nsp13-IN-6 can be used for researching anti-COVID-19 |
Product Information
| Synonyms | SARS-CoV-2 nsp13-IN-6|HMS3515C20|ZINC15785978|CCG-191343|HY-150632|CS-0535054|N-(6-methoxy-1,3-benzothiazol-2-yl)-2-(4-oxo-6,7,8,9-tetrahydropyrimido[4,5-b]quinolin-3(4H)-yl)acetamide |
| Molecular Weight | 421.47 |
| Molecular Formula | C21H19N5O3S |
| Canonical SMILES | COC1=CC2=C(C=C1)N=C(S2)NC(=O)CN3C=NC4=C(C3=O)C=C5CCCCC5=N4 |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 706 |
| Exact Mass | 421.12086066 |
| Target | IC50: 27 μM (ssDNA+ ATPase), 33 μM (ssDNA- ATPase) |
| XLogP3-AA | 3 |
